Health 29 sources · over 5 days 46 articles

Moderna Cancer Vaccine Data Leak Sends Shares Tumbling Despite Trial Success

Moderna and Merck's melanoma vaccine delivered positive trial results, but a sharp stock selloff exposed the gap between investors' expectations and doctors' assessment of its potential.

Read the full story → · Latest coverage 26 Oct 2026, 8:21 pm UTC

Chapters · 3

  1. 1Moderna shares plunge after cancer vaccine data leak unsettles investors
  2. 2Moderna Cancer Vaccine Data Leak Triggers Selloff Despite Positive Trial Results
  3. 3Moderna Cancer Vaccine Data Leak Sends Shares Tumbling Despite Trial Success

Key moments · 10

Unverified vaccine report circulates on social platform X

ABC ↗

Moderna shares plunge about 25%, reversing vaccine optimism

Forbes ↗

Full trial data released later Thursday appear positive

CNBC ↗

Coverage gives conflicting figures for the reported benefit

Financial Times ↗

Reports detail 42% reduction in melanoma recurrence or death

CNN Brasil ↗

New coverage reports reduced risk of melanoma spreading

Times now ↗

Melanoma specialists call vaccine results clinically meaningful

CNBC ↗

Reports say personalised vaccine could win US approval in 2027

New Scientist ↗

After trial presentation, focus shifts to expanding treatment impact

STAT News ↗

Moderna CEO sees potential beyond melanoma treatment

Bloomberg ↗

Coverage by day

newest first

6 articles

  1. This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
    Inc.com Startups
  2. Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
    Bloomberg
  3. The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
    MarketWatch
  4. Vaccino anti cancro a mRNA abbatte rischio di recidiva o morte per melanoma, Ascierto: “Nuova era per oncologia”
    Fanpage
  5. Moderna CEO on what’s next after success in cancer vaccine - STAT
    STAT

2 articles

  1. STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
    STAT News
  2. The world’s first-ever cancer vaccine has slashed the risk of tumour recurrence by a staggering 42 per cent in clinical…
    sozootoday

3 articles

  1. Melanoma, primo vaccino 'su misura' riduce il rischio di recidiva del 42%
    RSS di - ANSA.it
  2. Personalised cancer vaccine cuts skin cancer recurrence risk by 42%: What this means for patients
    Indian Express
  3. A Cancer Vaccine Made Just For You? Personalised mRNA Jab Cuts Melanoma Recurrence Risk By 49% In Major Trial
    Top World News- News18.com

18 articles

  1. Oncologists Cheer Melanoma Data
    Bloomberg
  2. A personalized cancer vaccine could be available as soon as 2027. Here’s what we know
    Fast Company
  3. The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
    MarketWatch
  4. Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
    NBC News
  5. Moderna e Merck divulgam dados de vacina contra câncer após vazamento nas redes sociais
    Notícias ao Minuto

16 articles

  1. A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
    TIME.com
  2. ‘Landmark moment’: Sydney scientist’s world-first cancer breakthrough revealed
    Sydney Morning Herald
  3. Here’s what Moderna’s latest mRNA cancer vaccine data actually show
    Scientific American Content: Global Science
  4. A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
    Top Stories
  5. Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    Ars Technica Tech